New leaflet on RefluG™ Isorepair, the medical device for esophageal mucosal defence

15 July 2020

RefluG™ Isorepair is a patented medical device (class IIa) with long-lasting action for the treatment of gastroesophageal reflux symptoms.

Ask for your free copy of the new leaflet of RefluG™ Isorepair, fill in the form!

Gastroesophageal reflux is a common disorder that happens when the stomach content flows back into the esophagus and, due to its acidity and its irritant components, it may cause damage to the esophageal mucosa, the appearance of lesions and symptoms such as acid regurgitation, burning, retrosternal pain, and irritative cough.

RefluG™ Isorepair is designed to reduce gastroesophageal reflux symptoms by exerting multiple mechanical actions on the esophageal mucosa surface (protective, soothing, lubricant). It can be used both in combination with proton pump inhibitors and H2 antagonists, and it is available in ready-to-take liquid sachets.

  • Protective action able to promote repair processes of the esophageal mucosa thanks to the presence of hyaluronic acid and an amino acid complex (proline, hydroxyproline, and glutamine). Thanks to its known water storage properties, hyaluronic acid creates a protective film on the esophageal mucosa protecting it from damage. In addition, the synergistic effect of hyaluronic acid and amino acids favors the physiological repair processes of the esophageal mucosa, which may be compromised in the event of gastroesophageal reflux.
  • Anti-irritative action promoted by the VGF™ plant complex which, with its emollient properties, helps to reduce irritation of the esophageal mucosa.
  • Lubricant action favored by the filming effect of the medical device.

The efficacy, safety, and tolerability of RefluG Isorepair have been proven and documented in clinical and pre-clinical trials confirming its ability to promote the natural repair processes of the esophageal mucosa.

Discover RefluG™ Isorepair, a patented class IIa MD, ask for your free copy of the new leaflet!

SUBSCRIBE TO OUR NEWSLETTER

Stay updated on news

* indicates required